Eterna Therapeutics
ERNA
34 hedge funds and large institutions have $5.66M invested in Eterna Therapeutics in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 22 closing their positions.
4,700% more call options, than puts
Call options by funds: $96K | Put options by funds: $2K
0% less ownership
Funds ownership: 0% → 0% (-0%)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
31% less funds holding
Funds holding: 49 → 34 (-15)
59% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 22
85% less capital invested
Capital invested by funds: $38.4M → $5.66M (-$32.8M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$603K |
| 2 |
Millennium Management
New York
|
+$316K |
| 3 |
E
Ergoteles
New York
|
+$136K |
| 4 |
Two Sigma Investments
New York
|
+$115K |
| 5 |
Goldman Sachs
New York
|
+$57.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.13M |
| 2 |
AC
Armistice Capital
New York
|
-$1.11M |
| 3 |
Morgan Stanley
New York
|
-$660K |
| 4 |
State Street
Boston,
Massachusetts
|
-$423K |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$241K |
ERNA Hedge Fund Activity: Q2 2022 in Review
34 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q2 2022, worth a combined $5.66M — down 85% from $38.4M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ERNA and 9 opened new positions — a net loss of 13 holders — while 11 trimmed existing stakes and 8 added.
The largest buyer was Renaissance Technologies, adding an estimated $603K. The largest seller was BlackRock, cutting an estimated $1.13M.
- 34 institutional investors held Eterna Therapeutics (ERNA) as of Q2 2022, down from 49 in Q1 2022.
- Funds reported $5.66M of Eterna Therapeutics stock for Q2 2022, down 85% quarter-over-quarter.
- 9 funds opened new Eterna Therapeutics positions in Q2 2022 and 22 closed out, a net change of -13 holders.
- The largest Eterna Therapeutics buyer in Q2 2022 was Renaissance Technologies, an estimated $603K added.
- The largest Eterna Therapeutics seller in Q2 2022 was BlackRock, an estimated $1.13M sold.
Based on aggregated 13F filings for Q2 2022.